 "Covaxin has started trials on children; it would be for children who are two years or older")
The Lancet publication, a peer-reviewed medical journal, has expressed a mixed opinion about Covaxin, a Covid-19 vaccine developed by Bharat Biotech.
In summary, it said that the “interim phase 3 report (funded by Bharat Biotech and Indian Council of Medical Research) suggests BBV152 Covid-19 vaccine (the scientific name for Covaxin) is safe and protects against disease”.
Extrapolating from the report, Lancet said ‘two doses offer 77.8 per cent protection against symptomatic Covid-19’. This compares favourably with Serum Institute of India’s (SII’s) Covishield vaccine developed by Oxford University.
However, The Lancet goes on to add: “Further research is needed to determine the vaccine’s long-term
